• Careers
  • News
  • Publications
  • Contact Us
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Collaborations
    • Careers
    • Contact Us
  • Science
    • Onco-Metabolism Platform
    • Therapeutic Areas
    • Publications
  • Programs
    • Pipeline
    • Glutaminase Inhibitor Telaglenastat
    • Arginase Inhibitor INCB001158
    • Arginase Inhibitor
      CB-280
    • CD73 Inhibitor
      CB-708
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access
  • Media & Investors
    • Corporate Profile
    • Press Releases
    • Event & Presentations
    • Stock Information
    • Financial Information
      • Overview
      • SEC Filings
      • Ownership Summary
    • Analyst Coverage
    • Corporate Governance
      • Highlights
      • Board of Directors
      • Management Team
      • Committee Composition
    • Shareholder Services
      • Investor FAQs
      • E-mail Alerts
    • Proxy & Annual Report
    • Contact Us
  • Careers
  • News
  • Publications
  • Contact Us

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Development Pipeline

Calithera is pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.

Learn More

Development Pipeline

Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.

Learn More

Culture

Science

Recent News

December 6, 2019

Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

December 5, 2019

Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 12, 2019

Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

November 5, 2019

Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 4, 2019

Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

View All
Company
  • About Us
  • Management Team
  • Board of Directors
  • Collaborations
  • Careers
  • Contact Us
Science
  • Onco-Metabolism Platform
  • Therapeutic Areas
  • Publications
Programs
  • Pipeline
  • Glutaminase Inhibitor Telaglenastat (CB-839)
  • Arginase Inhibitor INCB001158
  • Arginase Inhibitor CB-280
  • CD73 Inhibitor CB-708
Clinical Trials
  • Clinical Trial Overview
  • Expanded Access
Media & Investors
  • Corporate Profile
  • Press Release
  • Events & Presentations
  • Stock Information
  • Financial Information
  • Analyst Coverage
  • Corporate Governance
  • Shareholder Services
  • Proxy & Annual Report
  • Contact Us
ETHICS & COMPLIANCEPRIVACY POLICYLEGAL TERMS OF USE
  • Contact Us
  • News
Copyright © 2019 Calithera. The CALITHERA name is the registered trademark of Calithera Biosciences, Inc. All Rights Reserved.
Copyright © 2019 Calithera. The CALITHERA name is the registered trademark of Calithera Biosciences, Inc. All Rights Reserved.